Trump tariffs are taxes on imported goods that President Donald Trump has imposed to protect American manufacturers and reduce the trade deficit. As of April 2026, the average effective U.S. tariff rate stands at 13.7% following a February 2026 Supreme Court ruling that struck down some of the tariff authority used in 2025, when rates had peaked at 27%—the highest level in over a century. For example, steel tariffs reach up to 50%, while a new 100% tariff on patented pharmaceuticals took effect in early April 2026.
This article explains how these tariffs work, which products are affected, their economic impact on American households, and what happens next as some tariff authority expires later this year. The tariff system is more complicated than simply raising rates across the board. Different tariffs operate under different legal authorities—some are rooted in trade laws dating to 1962, others were deemed unconstitutional by the Supreme Court. The government had collected $166 billion from over 330,000 businesses in tariffs that the court later ruled violated the International Emergency Economic Powers Act. Understanding which tariffs remain in place, which are expiring, and which are brand new is essential for businesses, consumers, and anyone concerned about inflation and household costs.
Table of Contents
- What Are Trump Tariffs and How Do They Work?
- Current Tariff Rates and What’s Being Taxed
- The Household Economic Impact of Tariffs
- Sector-Specific Impacts and Business Consequences
- The Supreme Court Ruling That Changed Everything
- Trade Deficit Improvements and the Mixed Job Picture
- The New Pharmaceutical Tariff Frontier
- Conclusion
What Are Trump Tariffs and How Do They Work?
trump tariffs are taxes imposed on foreign goods entering the United States, with the stated goal of encouraging Americans to buy domestic products and pressuring trading partners to negotiate more favorable deals. When a tariff is imposed, the importing company typically passes the cost to distributors, retailers, and ultimately consumers. For instance, if a 25% tariff is placed on imported steel, a U.S. car manufacturer buying that steel might see production costs rise, and those increased costs often get reflected in the price of vehicles on dealer lots. The tariff revenue is collected by U.S.
Customs and collected directly into the federal Treasury—in 2026, the Tax Policy Center estimates tariffs will generate $194 billion in revenue, with $963 billion projected over the next decade. Tariffs operate under different legal authorities. Some derive from Section 232 of the Trade Expansion Act of 1962, which allows the president to impose tariffs to protect national security. Others come from Section 122, which allows a president to impose surcharges on imports during an emergency. The critical difference: in February 2026, the Supreme Court ruled 6-3 that the International Emergency economic Powers Act (IEEPA) does not actually authorize tariffs, invalidating a key legal justification for tariff increases in 2025. This ruling effectively reset the tariff landscape, though certain tariffs under Section 232 and Section 122 remain lawful and in place.
Current Tariff Rates and What’s Being Taxed
The current average effective U.S. tariff rate of 13.7% represents a significant increase from the pre-2025 average of 2.5%, but it’s substantially lower than the 27% peak that occurred early in 2025 when tariff authority was at its broadest. Understanding which specific products face which rates is important: steel faces tariffs up to 50%, aluminum and copper carry elevated rates, automobiles and derivative products are subject to Section 232 tariffs, and apparel and leather goods face steep tariff schedules. However, not all imports are affected equally—the system is complex, with different rates applying to different product categories and countries.
A critical development in April 2026 is the 100% tariff on patented pharmaceuticals, set to take effect in 120 days for large pharmaceutical companies and 180 days for smaller manufacturers. This represents a dramatic escalation that could significantly impact drug prices and availability of medications, particularly for expensive specialty drugs. The pharmaceutical industry has flagged concerns about supply chain disruption and potentially higher medication costs for American patients. Meanwhile, the Section 122 across-the-board 10% surcharge on nearly all countries remains in place but is set to expire on July 24, 2026—unless Congress votes to extend it. This expiration date creates significant business uncertainty for importers planning purchases for the second half of 2026.
The Household Economic Impact of Tariffs
The average American household is bearing the cost of these tariffs. The Tax Policy Center estimates the cost at approximately $1,500 per household in 2026, making this the largest U.S. tax increase as a percentage of GDP since 1993. Other estimates are somewhat lower—Yale Budget Lab and Tax Foundation projections range from $570 to $700 per household—but all estimates point in the same direction: tariffs are a meaningful financial burden on American families. These costs show up invisibly: in higher prices at grocery stores for goods in thin-profit-margin categories, in more expensive clothing and shoes, in elevated prices for electronics and appliances.
The inflation effect has been documented by major financial institutions. Goldman Sachs estimates that tariffs contributed to a 0.5% increase in inflation in 2025, with an additional 0.3% inflation expected in the first six months of 2026. This contributed to higher Social Security cost-of-living adjustments (COLA) for 2026, meaning beneficiaries received larger raises but also face higher prices for goods and services. The hardest-hit product categories are apparel and leather goods (shoes, handbags), high-metal-content products (electronics and electrical equipment), and motor vehicles. These are items most Americans purchase regularly, so tariff impacts reach across income levels and regions.
Sector-Specific Impacts and Business Consequences
Different sectors of the economy experience tariffs very differently. Manufacturers that rely on imported materials—such as automobile producers, electronics manufacturers, and consumer goods companies—face direct cost increases that flow through to consumers. A automotive company purchasing imported steel or components now pays more, which either reduces profit margins or gets passed to the customer through higher car prices. Small businesses importing goods face the same tariff burden as large corporations, yet lack the negotiating power or scale to absorb costs, making the tariff environment particularly challenging for smaller importers and retailers. The comparison between sectors reveals disparities.
A domestic steel manufacturer benefits from tariff protection as foreign competition becomes more expensive, creating incentive to maintain or expand U.S. production. Conversely, a U.S. company that uses imported steel in its manufacturing process—say, a appliance maker or construction equipment producer—faces higher input costs and reduced competitiveness internationally because foreign competitors may have cheaper steel access. Low-margin retail businesses selling imported groceries, clothing, or electronics face particular pressure because they cannot easily raise prices without losing sales to competitors. Some business sectors, particularly agriculture and raw material producers, have benefited from tariff protection, while downstream manufacturers and consumers bear the burden.
The Supreme Court Ruling That Changed Everything
In February 2026, the Supreme Court delivered a landmark decision that fundamentally reshaped the tariff landscape. The court ruled 6-3 that the International Emergency Economic Powers Act (IEEPA), which had been cited as justification for many of the 2025 tariff increases, does not actually authorize tariffs. This ruling created a massive liability: the federal government had collected $166 billion in tariffs from over 330,000 businesses under this invalid legal authority. The practical consequence is that tariffs previously imposed under IEEPA authority were stripped of their legal foundation, though the government has not announced comprehensive refund plans.
The court’s decision did not invalidate all tariffs—Section 232 tariffs (steel, aluminum, automobiles) and Section 122 surcharges remain lawful under their respective statutory authorities. However, the ruling exposed the precarious legal ground on which some tariff authority rests. Businesses that paid tariffs under the invalidated authority have potential legal claims for refunds, though navigating the claims process remains unclear. The ruling also created uncertainty about future tariff authority: presidents now have a clearer sense of which statutory authorities actually permit tariffs and which do not. This legal instability complicates planning for businesses affected by tariffs, since future court decisions could invalidate additional tariff categories.
Trade Deficit Improvements and the Mixed Job Picture
One of Trump’s stated objectives—reducing the chronic U.S. trade deficit—has shown tangible results. Ten consecutive months of decline in the trade deficit have occurred as higher tariffs discourage imports and domestic demand shifts toward American-made products. This represents genuine policy success by the administration’s metrics.
However, the broader employment and economic picture is more complex: factory jobs have actually declined despite the trade deficit improvement, and inflation remains elevated. The tariff policy has achieved one goal (trade deficit reduction) while the labor market shows weakness in the very sectors tariffs were designed to protect. This disconnect raises important questions about tariff effectiveness as a job creation tool. If tariffs reduce the trade deficit but manufacturing employment falls, something else is driving job losses—potentially automation, structural industry changes, or insufficient investment in factory expansion despite tariff protection. The gap between policy intention (protect and create manufacturing jobs) and actual outcome (trade deficit down, factory jobs down) suggests that tariffs alone are insufficient to guarantee employment gains.
The New Pharmaceutical Tariff Frontier
As of April 2, 2026, the Trump administration imposed a 100% tariff on patented pharmaceutical products, taking effect in 120 days for large pharmaceutical companies and 180 days for smaller manufacturers. This represents uncharted territory in tariff policy: it targets branded medications rather than raw materials or finished consumer goods. The tariff is designed to pressure pharmaceutical companies to lower drug prices, operating on the theory that tariff costs will force companies to reduce prices rather than absorb the tariff burden. However, this approach risks unintended consequences: companies could reduce R&D investment in new drug development, withdraw from certain market segments, or restrict supply to the U.S. market rather than accept the tariff costs.
The pharmaceutical tariff also raises questions about implementation timing. The staggered implementation (120 vs. 180 days) suggests different regulatory treatment for large and small companies, though the practical effects remain uncertain. Given that many Americans already struggle with medication costs, a policy designed to reduce drug prices through tariff pressure could paradoxically increase costs if companies pass tariffs to consumers rather than absorb them as forced price reductions. The pharmaceutical sector will be a critical watch point as this tariff takes effect.
Conclusion
Trump tariffs in 2026 represent a complex and evolving policy landscape. The average effective tariff rate of 13.7% remains substantially elevated from pre-2025 levels, though a Supreme Court ruling invalidated some 2025 tariff authority and created $166 billion in potential refund liability. Steel, aluminum, automobiles, and apparel face explicit tariffs, while a new 10% across-the-board surcharge expires July 24, 2026. The pharmaceutical tariff beginning in April 2026 adds a new dimension to trade policy, with uncertain effects on drug prices and supply.
The economic impact on American households is substantial and measurable: an estimated $1,500 per household cost in 2026, contribution to inflation increases of 0.5% to 0.8% depending on the time period, and disproportionate impacts on low-margin retailers and consumers who buy apparel, electronics, and imported goods. The trade deficit has declined significantly, supporting the administration’s core objective, though manufacturing employment has not grown correspondingly. As the Section 122 surcharge expires in July 2026, Congress and the administration will face decisions about whether to extend existing tariffs or implement new ones. Businesses should monitor both the July 24 expiration date and the pharmaceutical tariff implementation timelines, as these will meaningfully affect costs and supply chains.